Sai Parenteral’s Ltd., incorporated in 2001, operates in the pharmaceutical formulations segment with activities spanning research, development, and manufacturing. The company functions across two primary segments: branded generic formulations and contract development and manufacturing organisation (CDMO) services for both domestic and international markets. Its product portfolio covers multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, dermatology, and vitamins, minerals, and supplements. These products are offered in various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments, reflecting a diversified formulation presence.
The company supplies its products to a broad customer base that includes government institutions, pharmaceutical companies, hospitals, and distribution networks within India. It commenced export operations in FY 2023 following the acquisition of two internationally accredited facilities in Hyderabad, Telangana, enabling access to regulated and semi-regulated markets such as Australia, New Zealand, Southeast Asia, the Middle East, and Africa. Sai Parenteral’s Ltd. operates five manufacturing facilities across India, including units with GMP, WHO-GMP, and international accreditations. As of December 31, 2025, the company had 298 full-time employees supporting its operations.